iPSC Generation Services: From PBMCs, Fibroblasts, And More.

iPSCs are typically reprogrammed by introducing products of specific sets of pluripotency-associated genes, or “reprogramming factors,” called Yamanaka factors. It requires extensive technical expertise to generate robust, karyotype-normal, and pluripotent cells.

With >15 years of expertise in stem cell technologies and as a leading provider of iPSC services, we can generate iPSCs safely and efficiently in 2-3 months.

When it comes to reprogramming, we don’t believe in a one-size-fits-all approach. We offer reprogramming using various vectors, including retrovirus, lentivirus, episomal plasmid, and direct delivery of synthetic mRNAs.

Our decision on the reprogramming method is based on the specific cell being reprogrammed and the method’s ability to adequately reprogram this cell type. We also assess whether the presence of integrated sequences in the iPSCs will hinder downstream applications, and we deliver iPSCs that are ideal for your basic research, drug discovery, drug screening, and preclinical cell regeneration projects.

• Highly optimized protocols with high reprogramming efficiency (>95% success rate)
• From healthy/diseased human or non-human samples
• iPSC generation from various donor cell types
  • human: PBMCs, fibroblast, HSC, MSCs, CD34+ cord blood, urine, and more
  • non-human: PBMC and fibroblast
• Integration-free (episomal/mRNA/viral-based) or retroviral reprogramming
• Feeder-free protocols; optional feeder-dependent protocols available
• iPSCs characterized for morphology and pluripotency markers. Additional characterization such as G-banding, RT-PCR, STR profiling, and directed differentiation is also available.
• Fast Turnaround: 2-3 months
• GMP iPSC Generation Available

If you are looking for additional downstream project support, our team can genetically engineer your iPSCs using CRISPR/Cas9 or TARGATT™ and differentiate the iPSCs to the cell type of your choice, including NK cells, T cells, astrocytes, cardiomyocytes, and more.

^Publications

• ^{Jang, Y., Choi, J., Park, N., Kang, J., Kim, M., Kim, Y., & Ju, J. H. (2019). Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering. Experimental & Molecular Medicine, 51(1), 3.}
• ^{Ilic, D. (2019). Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions in October 2018. Regenerative medicine, 14(2), 85-92.}
• ^{Allende, M. L., Cook, E. K., Larman, B. C., Nugent, A., Brady, J. M., Golebiowski, D., ... & Proia, R. L. (2018). Cerebral organoids derived from Sandhoff disease induced pluripotent stem cells exhibit impaired neurodifferentiation. Journal of Lipid Research, jlr-M081323.}
• ^{Field, A. R., Jacobs, F. M., Fiddes, I. T., Phillips, A. P., Reyes-Ortiz, A. M., LaMontagne, E., ... & Hauessler, M. (2019). Structurally Conserved Primate LncRNAs Are Transiently Expressed during Human Cortical Differentiation and Influence Cell-Type-Specific Genes. Stem cell reports.}